

## PERSONAL INFORMATION

## Margherita Muratore

📍 via Edison 217, 92023 campobello di licata (Italy)

📞 3886933162

✉ margaret137@hotmail.it

## WORK EXPERIENCE

01/11/2020 – Ongoing Oncologist at Dipartimento per la Tutela della salute della Donna e della Vita Nascente – UOC Senologia Medica

01/02/2020–31/10/2020 Training at *Dipartimento per la Tutela della Salute della Donna e della Vita Nascente* Day Hospital of *Farmacologia Clinica, Policlinico Universitario Agostino Gemelli IRCCS* of Rome

Sub-investigator of the following clinical studies (Phase II / III), according to GCP, in the field of breast and gynecological cancer:

- ENGOT-ov50 / GOG-3029 / INNOVATE-3: pivotal, randomized, open-label study of tumor treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer
- MITO END-3: a randomized phase II trial of Carboplatin+Paclitaxel compared to Carboplatin+Paclitaxel+Avelumab in advanced (Stage III-IV) or recurrent endometrial cancer
- ENGOT-OV43/KEYLYNK-001: a phase III, randomized, double-blind, active- and placebo-controlled study of pembrolizumab plus chemotherapy with olaparib maintenance for first-line treatment of BRCA-nonmutated advanced epithelial ovarian cancer.
- AGO-DUO: a Phase III randomised, double-blind, placebo-controlled, multicentre study of Durvalumab in combination with chemotherapy and Bevacizumab, followed by maintenance Durvalumab, Bevacizumab and Olaparib in newly diagnosed advanced ovarian cancer patients (DUO-O) - D081RC00001 DUO-O; ENGOT-ov46; AGO-OVAR 23; GOG-3025'
- MITO 29: randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
- ATHENA: a multicenter, randomized, double-blind, placebo- controlled phase 3 study in ovarian cancer patients evaluating Rucaparib and Nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy
- CORT: phase II, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer treated with intermittent or continuous regimens of relacorilant in combination with nab-paclitaxel compared with patients treated with nab-paclitaxel alone.
- ENGOT-cx8/BGOG-cx8/GCT1015-05: phase 2 open-label trial of Tisotumab Vedotin (HuMax® - TF- ADC) alone or in combination in first line recurrent or stage IVB cervical cancer
- ENGOT-cx9/GEICO/REGN: open-label, randomized, GOG/ENGOT phase 3 trial of anti-PD1 cemiplimab versus investigator's choice chemotherapy in >2 line recurrent cervical cancer.
- MK-3475-775/E7080-G000-309: pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice.
- LEAP-001: Pembrolizumab (MK-3475) plus Lenvatinib (E7080/MK-7902) versus chemotherapy for endometrial carcinoma
- IMPASSION 050: a phase III, randomized, double-blind, placebo-controlled clinical trial to Evaluate the efficacy and safety of atezolizumab or placebo in combination with neoadjuvant doxorubicin + cyclophosphamide followed by paclitaxel + trastuzumab + pertuzumab In early Her2-Positive

## Curriculum vitae

### breast cancer

- B991032: a phase II study to evaluate safety and anti-tumor activity of Avelumab in combination with Talazoparib in patients with BRCA or ATM mutant tumors
- ARIEL 3: study of rucaparib as switch maintenance following platinum-based chemotherapy in

patients with platinum-sensitive, high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer

- ARIEL 4: a study of rucaparib versus chemotherapy BRCA mutant ovarian, fallopian tube, or primary peritoneal cancer patients
- EUDARIO: European, multi-center, randomised three-arm open-label Phase II trial in mutp53, platinum-sensitive ovarian cancer patients. It evaluates the safety and efficacy of Ganetespib in combination with Carboplatin on one hand and the Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor Niraparib on the other hand in comparison to standard treatment options.
- MITO 26: Multicenter phase II study on trabectedin in patients advanced uterine and ovarian carcinosarcoma.
- MITO 23: open-label, prospective, multicenter, randomized Phase III, clinical trial evaluating the efficacy and safety of trabectedin in BRCA1 and BRCA2 mutation carrier and BRCAness phenotype advanced ovarian cancer patients in comparison to physician' choice chemotherapy.
- OREO: Phase IIIb, randomised, double-blind, placebo-controlled, multicentre study to assess the efficacy and tolerability of Olaparib retreatment, versus matching placebo, in non-mucinous epithelial ovarian cancer (EOC) patients (including patients with primary peritoneal and/or fallopian tube cancer).
- NUVOLA: neoadjuvant chemotherapy in Unresectable oVarian Cancer With OLaparib and weekly Carboplatin Plus Paclitaxel: a phase II open-label multicentre study
- BEATcc: phase II trial studies how well atezolizumab and bevacizumab work in treating patients with cervical cancer that has come back, remains despite treatment, or has spread to other places in the body. Monoclonal antibodies, such as atezolizumab and bevacizumab, may shrink tumor cell and interfere with the ability of tumor cells to grow and spread.

- 01/11/2015–31/01/2020 Resident in Medical Oncology , AOU Federico II, Naples, street Sergio Pansini 5
- Sub-investigator of the following clinical studies (Phase -III), according to GCP, in the field of Breast and gynecological cancer:
- FEDERICA: phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of Pertuzumab and Trastuzumab in combination with chemotherapy in patients with HER2-positive early breast cancer
  - IMPASSION 131: phase III, multicenter, randomised, double-blind, placebo-controlled study of Atezolizumab (Anti-Pd-L1 Antibody) in combination with paclitaxel compared with placebo with paclitaxel for patients with previously untreated inoperable locally advanced or metastatic triple negative breast cancer
  - LUCY: phase IIIb, single-arm, open-label multicenter study of olaparib in patients with HER2-negative metastatic breast cancer and a germline BRCA1/2 mutation
  - IMAGYN-050: phase III, multicenter, randomized, study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab to patients with newly- diagnosed stage III or stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  - TRAMANT: phase II study: Maintenance therapy with Trabectedin after combination therapy with Liposomal Doxorubicin and Trabectedin towards combination therapy with Liposomal Doxorubicin and Trabectedin in patients with ovarian cancer relapsed between 6 and 12 months after platinum-based chemotherapy.
- 18/08/2015–23/08/2015 Medical doctor in holiday spot for children 7/14 years old in Brindisi
- 08/11/2014–08/01/2015 Emergency medical care in Casteltermeni (ASP Agrigento)
- 08/07/2014–22/07/2014 Medical doctor in holiday spot for children 7/14 years old in Tivoli
- 15/06/2014–15/09/2014 Emergency medical care in Marina di Palma (ASP Agrigento)

## EDUCATION AND TRAINING

- 30/10/2020 Specialization in Medical Oncology with grades 50/50 cum laude  
AOU Federico II - via Sergio Pansini 5 -Naples
- 03/03/2020 Good Clinical Practice training meeting "Minimum criteria for ICHE6 GCP investigator Sitee Personnel Training"
- 08/11/2018 Good Clinical Practice training
- 05/02/2014 Medical Licensure 270/270 Ordine dei medici e chirurghi di Agrigento
- 23/07/2013 Degree in Medicine and Surgery 110/110 University of Palermo "Policlinico P. Giaccone"

- 01/07/2010–31/07/2010 Clerkship in the Public Clinic Of Medical University in Bialystock, Poland.
- 2003 High school diploma "Liceo classico statale Ugo Foscolo" 100/100, Canicattì (Agrigento)

## PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s) English

### Job-related skills Publication in international journals:

- The influence of preniinose on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer  
Buonerba C, Sonpavde G, Vitrone F, Bosso D, Puglia L, Izzo M, Iaccarino S, Scafuri L, Muratore M, Foschini F, Mucci B, Tortora V, Pagliuca M, Ribera D, Riccio V, Morra R, Mosca M, Cesarano N, Di Costanzo I, De Placido S, Di Lorenzo G.  
J Cancer. 2017 Aug 22;8(14):2663-2668. doi: 10.7150/jca.20040. eCollection 2017.
- Treatment Outcomes of Patients with Thymic Carcinoma; a monocentric Experience of sequential Regimen Modality.  
M.Ottaviano, M.Giuliano, P. Perrone, M. Tortora, M. Muratore, S. De Placido, G.Palmieri.  
Journal of Thoracic Oncology – Oct 2018
- Newly diagnosed ovarian cancer: Which first-line treatment?  
Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.  
Cancer Treat Rev. 2020 Oct 9;91:102111.
- Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.  
Lorusso D, Ceni V, Muratore M, Salutari V, Nero C, Pietragalla A, Ciccarone F, Carbone V, Daniele G, Scambia G.  
Expert Opin Emerg drugs 2020 Oct 20; 1-9.

### Congresses:

- 22/02/2019 Course Teacher : Target Therapy nei tumori rari: dalle evidenze scientifiche alla pratica clinica , ente organizzatore : AOU Federico II di Napoli
- 05/07/2019 Course Teacher: Tumore della mammella localmente avanzato: diagnosi radiologica, conferma istologica e pianificazione terapeutica – Ente organizzatore: AOU Federico II di Napoli
- 11/10/2019 Course Teacher: Tumore della mammella localmente avanzato: diagnosi radiologica, conferma istologica e pianificazione terapeutica – Ente organizzatore: AOU Federico II di Napoli
- 08/05/19 Course Teacher: Attualità e prospettive nel trattamento dei tumori femminili – Ente organizzatore: AOU Federico II di Napoli
- 24/01/2019 Course Teacher: niraparib nelle pazienti platino sensibili: attualità e prospettive - Ente organizzatore: tesaro bio italy s.r.l
- 25/09/2020 Course Teacher: Breast talent – Ente organizzatore: Fmp – Fondazione per la medicina personalizzata.

- 06/07/2018 Taking part: Terapie neoadiuvante del tumore mammario, dalle linee avanzate alla seconda linea – Ente organizzatore: AOU Federico II di Napoli
- 22/11/2016 – 26/11/2016 Taking part: 15 Stage in Oncologia Clinica – Ente organizzatore: Ospedale “ San Vincenzo” di Taormina
- 06/09/2018 – 07/09/2018 Taking part: Five shades of recurrence – Ente organizzatore: Policlinico Agostino Gemelli di Roma
- 06/11/2019 Taking part: Breast cancer retreat focus 2019: carcinoma mammario metastatico ER+/Her2- - Ente organizzatore: scuola medica della Campania
- 30/11/2018 – 01/12/2018: Taking part: METE: MEet The Experts in Ovarian Cancer” - Ente organizzatore: tesaro bio italy s.r.l
- 25/02/2019 -26/02/2019 Taking part: “TOP Thoracic Oncology Preceptorship” – Ente organizzatore: San Raffaele di Milano
- 28/11/2018 - 28/11/2018 Taking part: “1° GBO meeting” – Ente organizzatore: conquer breast
- 14/03/2019 - 15/03/2019 Taking part: “Breast Journal Club” – Ente organizzatore: Overscientific
- 12/10/2018 - 12/10/2018 Taking part: “Ruolo delle terapie nella cronicizzazione della recidiva del carcinoma ovarico” – Ente organizzatore: Accademia Nazionale di Medicina
- 19/09/2019 - 20/09/2019 Taking part: “Supernovae in oncologia” – Ente organizzatore: AIOM
- 28/11/2019 - 29/11/2019 Taking part: “Making a difference: leave no patient behind” – Ente organizzatore: Clovis oncology

Digital skills      Good level of knowledge and use of the following programs: Microsoft Word, Excel, Powerpoint, Internet Explorer

Driving licence      B